Financial Analysis: Relay Therapeutics (NASDAQ:RLAY) Vs. LadRx (OTCMKTS:CYTR)
Financial Analysis: Relay Therapeutics (NASDAQ:RLAY) Vs. LadRx (OTCMKTS:CYTR)
Relay Therapeutics (NASDAQ:RLAY – Get Rating) and LadRx (OTCMKTS:CYTR – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations.
接力治療公司(納斯達克：RLAY-GET評級)和LadRx(場外交易市場：Cytr-GET評級)都是醫療公司，但哪隻股票更好？我們將根據兩家公司的機構持股、盈利能力、收益、股息、估值、風險和分析師建議來比較它們的實力。
Risk & Volatility
風險與波動性
Relay Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, LadRx has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500.
Relay Treeutics的貝塔係數為1.01，這意味着其股價的波動性比標準普爾500指數高出1%。相比之下，LadRx的貝塔係數為1.96，這意味着其股價的波動性比標準普爾500指數高96%。
Profitability
盈利能力
This table compares Relay Therapeutics and LadRx's net margins, return on equity and return on assets.
下表比較了Relay Treeutics和LadRx的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Relay Therapeutics | -17,136.40% | -21.42% | -18.77% |
| LadRx | N/A | -67.61% | -45.39% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 接力治療學 | -17,136.40% | -21.42% | -18.77% |
| LadRx | 不適用 | -67.61% | -45.39% |
Valuation and Earnings
估值和收益
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Relay Therapeutics | $3.03 million | 821.13 | -$363.87 million | ($2.66) | -7.74 |
| LadRx | N/A | N/A | -$6.70 million | ($0.15) | -0.61 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 接力治療學 | 303萬美元 | 821.13 | -3.6387億美元 | ($2.66) | -7.74 |
| LadRx | 不適用 | 不適用 | -670萬元 | ($0.15) | -0.61 |
LadRx has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.
LadRx的收入低於Relay Treeutics，但收益高於Relay Treeutics。Relay治療公司的市盈率低於LadRx，這表明它目前是兩隻股票中更負擔得起的一隻。
Analyst Ratings
分析師評級
This is a summary of recent ratings and price targets for Relay Therapeutics and LadRx, as reported by MarketBeat.
據MarketBeat報道，這是Relay治療公司和LadRx公司最近的評級和目標價摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Relay Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| LadRx | 0 | 0 | 0 | 0 | N/A |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 接力治療學 | 1 | 1 | 5 | 0 | 2.57 |
| LadRx | 0 | 0 | 0 | 0 | 不適用 |
Relay Therapeutics presently has a consensus target price of $33.43, suggesting a potential upside of 62.43%. Given Relay Therapeutics' higher possible upside, equities research analysts clearly believe Relay Therapeutics is more favorable than LadRx.
Relay Treateutics目前的共識目標價為33.43美元，暗示潛在上漲62.43%。考慮到Relay治療公司更高的可能上行空間，股票研究分析師顯然認為Relay治療公司比LadRx更有利。
Insider and Institutional Ownership
內部人與機構持股
0.1% of LadRx shares are held by institutional investors. 4.4% of Relay Therapeutics shares are held by company insiders. Comparatively, 12.8% of LadRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
LadRx 0.1%的股份由機構投資者持有。Relay Treateutics 4.4%的股份由公司內部人士持有。相比之下，LadRx 12.8%的股份由公司內部人士持有。強大的機構持股表明，對衝基金、捐贈基金和大型基金管理公司相信，一隻股票有望實現長期增長。
Summary
摘要
LadRx beats Relay Therapeutics on 7 of the 12 factors compared between the two stocks.
在兩隻股票之間的12個因素中，LadRx在7個因素上擊敗了Relay Treateutics。
About Relay Therapeutics
關於接力療法
(Get Rating)
(獲取評級)
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
接力治療公司是一家臨牀階段的精準藥物公司。它致力於改變藥物發現過程，最初的重點是在有針對性的腫瘤學和遺傳病適應症中加強小分子治療發現。該公司的主要候選產品包括RLY-4008，這是一種口服成纖維細胞生長因子受體2(FGFR2)小分子抑制劑，正在對晚期或轉移性FGFR2改變的實體腫瘤患者進行首次人類臨牀試驗；RLY-2608，一種針對磷酸肌醇3激酶α的領先突變體-PI3KA抑制劑計劃；以及RLY-1971，一種口服蛋白酪氨酸磷酸酶同源區域2區域含磷酸酶-2的口服小分子抑制劑，正處於對晚期實體腫瘤患者的第一階段試驗。它與D.E.Shaw Research，LLC簽訂了合作和許可協議，通過使用D.E.Shaw Research專注於蛋白質運動分析的計算建模能力來研究某些生物靶標，以開發和商業化針對這些靶標的化合物和產品；以及Genentech，Inc.用於RLY-1971的開發和商業化。該公司前身為Alstery，Inc.，並於2015年12月更名為Relay Treateutics，Inc.。Relay治療公司成立於2015年，總部設在馬薩諸塞州劍橋市。
About LadRx
關於LadRx
(Get Rating)
(獲取評級)
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
LadRx公司是一家生物製藥公司，致力於發現和開發治療癌症患者的療法。該公司正在進行後期臨牀試驗的高級藥物結合物醛阿黴素是抗癌藥物阿黴素的一個版本。其臨牀前治療包括針對癌症的連接子激活藥物版本7、8、9和10。該公司前身為CytRx公司，並於2022年9月更名為LadRx公司。LadRx公司成立於1985年，總部設在加利福尼亞州洛杉磯。
Receive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《接力治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Relay Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。